Institute Associate Scientist II - In Vivo Pharmacology

Organization
University of Texas MD Anderson Cancer Center
Job Location
Houston, TX
Job Description

ORBIT (Oncology Research for Biologics and Immunotherapy Translation) is a novel organization within the MD Anderson Cancer Center (MDACC), Houston, Texas, with the mission of making MD Anderson Cancer Center a recognized leader in the discovery and development of innovative biologics that help patients to prevail over cancer disease. ORBIT is a centralized MDACC organization that will guide, inform, accelerate and execute the translation of novel discoveries into clinically relevant cancer bio-therapeutics. We are committed to biologics development with industry standard and aim line of sight for combining scientific excellence with commercialization.



Requirements: 

The successful candidate will join the in vivo group efforts in the characterization and development of monoclonal antibodies including those that function as immune modulators for the treatment of cancer. S/he will contribute to the ex vivo and in vivo studies for multiple research programs across the different stages of pre-clinical drug discovery. S/he will have Master’s degree and be proficient in in vivo experimentation, including standard methods of tumor implantation and dosing, proper handling of small molecule drugs or biologics, tumor measurement, health monitoring, and data collection and analysis. The candidate will demonstrate the ability to perform and report complex in vivo preclinical cancer models. Experience in the pharmaceutical or biotech industry is preferred.

A research duo finds that science and technology graduate students who turn away from academic careers do so because of changes in their own interests.

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.

Gladys Kong writes at Fortune that her STEM background has helped her as a CEO.